论文部分内容阅读
当年,如果创新失败,团队所有成员的家财将收为银行所有。如今,康辰药业已是中国制药企业中罕有的拥有四个一类新药的企业,康辰创始人王锡娟十分感概——1998年初,王锡娟和她的团队在中国华南地区的尖吻蝮蛇蛇毒中,发现了一种新的止血活性成分,由此开启了国家一类新药“苏灵”的漫长创制历程。一类新药,亦即国内外均没有上市的药品。作为康辰医药董事长的王锡娟,看到了中国丰富的尖吻蝮蛇资源开发的价值和中国自主知识产权在蛇毒止血药市场的空白,她一心想挖掘这个价值、填补这个空白。
That year, if innovation fails, all members of the team’s family property will be collected by the bank. Now Kangchen is already a rare enterprise in China with four types of new drugs. Wang Xijuan, the founder of Kangchen, is very sensible - in early 1998, Wang Xijuan and her team were stinging in southern China In the snake venom, a new hemostatic active ingredient was discovered, thus opening up a long history of creation of a new national drug “Suling”. A class of new drugs, that is, no drugs listed at home and abroad. Wang Xijuan, chairman of Kangchen Pharmaceutical Group, saw the value of China’s abundant development of Agkistrodon furus and the gap in the Chinese snake venom hemostatic drug market. She was bent on tapping this value to fill this gap.